CareDx (CDNA) Q1 2026 earnings review
Transformational Quarter: High Growth, Major M&A, but ASP Quality Needs Scrutiny
CareDx delivered a blockbuster Q1 2026, with revenue surging 39% YoY to $118M and Adjusted EBITDA quadrupling to $19M. The company is aggressively restructuring its portfolio: simultaneously divesting its lagging, low-margin Lab Products business for $170M and acquiring Naveris, a high-growth oncology diagnostics firm, for $160M. However, investors must look under the hood. While testing volume grew a healthy 17%, the 48% spike in testing revenue was heavily subsidized by $14M in prior-period cash collections. Despite this one-time padding, the underlying momentum driven by Epic Aura integrations and Revenue Cycle Management (RCM) success gives management the confidence to significantly raise 2026 guidance and authorize a $100M buyback.
🐂 Bull Case
Swapping the stagnant Lab Products business (-4% YoY) for Naveris's oncology platform ($34M revenue, growing 30-40%) immediately expands CareDx's TAM into the $4.5B viral-mediated cancer market while focusing operations on high-margin testing.
Revenue grew 39% while operating expenses grew much slower, transforming a $10M GAAP net loss a year ago into a $3M net profit. RCM initiatives are driving record cash collections.
🐻 Bear Case
Average revenue per test spiked to $1,660, but this includes $14M in prior-period collections. Excluding this, underlying ASP is closer to $1,400, meaning organic revenue growth is materially lower than the headline 48% figure.
The looming finalization of the draft Medicare LCD (Local Coverage Determination) for solid organ transplants is expected to hit mid-year. Previous management commentary baked in a $7.5M headwind, which could threaten H2 margins.
⚖️ Verdict: 🟢
Bullish. The strategic pivot toward high-margin, high-growth segments via the Naveris acquisition and Lab Products divestiture is textbook capital allocation. While the $14M prior-period collection inflates current metrics, the underlying volume growth (+17%) and raised guidance show a company accelerating into a stronger competitive position.
Key Themes
Aggressive and Accretive Capital Reallocation
CareDx is aggressively reshaping its business. The company is selling its Lab Products division (which saw revenue decelerating to -4% YoY) to Eurobio Scientific for $170M. It is immediately deploying $160M of that cash to acquire Naveris, bringing in the NavDx test for HPV-driven cancers. This moves CareDx from a pure-play organ transplant company into precision oncology, swapping a declining legacy segment for one projected to grow 30-40% annually.
Epic Aura Integration Driving Frictionless Volume
Management's strategy to embed test ordering directly into hospital EMRs via Epic Aura is accelerating. The company now has 9 centers live and 16 integrations in process. This reduces clinician friction, minimizes login-related issues, ensures cleaner claims data upfront, and correlates directly with the stable 17% YoY growth in testing volume (54,900 tests in Q1).
Launch of VANTx AI Platform
CareDx introduced VANTx, an AI-powered, cloud-native data analytics platform. By analyzing complex transplant data, the platform aims to generate real-world evidence and support clinical research. This deepens the company's 'solution selling' moat, binding transplant centers tighter to CareDx's digital ecosystem.
Revenue Quality Propped Up by Prior-Period Collections
While Testing Services revenue skyrocketed 48% YoY to $91M, $14M of this came from prior-period collections. This inflated the Average Selling Price (ASP) to $1,660. Removing this one-time benefit puts the core ASP at roughly $1,400. While RCM improvements are real, investors should not expect 48% revenue growth to be the new sustainable baseline once the backlog of old claims is fully cleared.
Pending Medicare LCD Finalization
The company's materials omitted discussion of the draft Medicare Local Coverage Determination (LCD) for solid organ transplants, which was previously expected to finalize mid-year 2026. In late 2025, management guided for a $7.5M negative impact from this policy. The silence in the Q1 release leaves this as a looming operational risk.
Shareholder Returns Re-Prioritized
Following an $88M stock repurchase in 2025, the Board authorized a new $100M buyback program over the next 24 months. Combined with the M&A activity, management is heavily utilizing its balance sheet (which held $187M in cash and marketable securities prior to the M&A shuffle) to engineer shareholder value.
Other KPIs
Accelerating sequentially from 53,000 in Q4 2025. YoY growth of 17% demonstrates that underlying clinical demand remains robust, independent of the pricing and collection tailwinds.
Accelerating dramatically from 68% in Q1 2025. The 500-basis-point expansion is largely attributable to the high margin flow-through of the $14M in prior-period cash collections, as the cost for these tests was recognized in previous quarters.
Reversing from a cash burn of $26.6M in Q1 2025. A record quarter for cash collections proves that the investments in AI-driven Revenue Cycle Management are permanently improving working capital dynamics.
Guidance
Accelerating. The new midpoint ($456M) represents a roughly 20% YoY increase over FY2025's $379.8M, a significant acceleration from the 14% growth seen last year. This reflects strong Q1 momentum and likely bakes in sustained pricing strength, though it does not clarify if Naveris revenue is included.
Accelerating. The midpoint of $50M implies an enormous ~41% YoY jump compared to the roughly $35.5M generated in FY2025. This underscores massive operating leverage as the company scales its Epic Aura integrations and phases out the lower-margin Lab Products business.
Key Questions
Naveris Integration and Guidance
Does the raised 2026 revenue guidance ($447-$465M) include the projected $34M in revenue from the Naveris acquisition, or is this purely organic growth from the core transplant business?
Sustainable ASP Baseline
With $14M of Q1 testing revenue coming from prior-period collections, what is the internally modeled normalized Average Selling Price (ASP) we should expect for the remainder of 2026 as the historical claims backlog normalizes?
Medicare LCD Update
What is the latest intelligence on the timing and final language of the Medicare LCD for solid organ transplant monitoring, and does the raised EBITDA guidance still assume the $7.5M mid-year headwind previously discussed?
Lab Products Divestiture Mechanics
With the sale of the Lab Products division to Eurobio Scientific, how much stranded overhead cost will remain, and what is the exact timeline for deconsolidating this revenue from the financials?